6a6h

From Proteopedia
Jump to navigation Jump to search

Crystal Structure of Swine Major Histocompatibility Complex Class I SLA-2*040202 For 2.3 AngstromCrystal Structure of Swine Major Histocompatibility Complex Class I SLA-2*040202 For 2.3 Angstrom

Structural highlights

6a6h is a 3 chain structure with sequence from Foot-and-mouth disease virus A and Sus scrofa. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 2.31Å
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

Q8MHU4_PIG

Publication Abstract from PubMed

Presentation of viral epitopes by swine MHC I (termed leukocyte antigen class I, SLA I) to cytotoxic T lymphocytes (CTLs) is crucial for swine immunity. The SLA-2 structure, however, remains largely unknown. To illustrate the structural basis of swine CTL epitope presentation, the crystal structure of SLA-2*04:02:02 complexed with one peptide, derived from foot-and-mouth disease virus (FMDV), was analyzed in this study. SLA-2*04:02:02 and swine beta2-microglobulin (sbeta2m) were refolded in vitro in the presence of peptides. X-ray diffraction data of SLA-2*04:02:02-peptide-sbeta2m (referred to as p/SLA-2*04:02:02) were collected. The diffraction dataset was 2.3 A in resolution and the space group was P3(2)21. Relevant data included a = 101.8 A, b = 101.8 A, c = 73.455 A,alpha = 90.00 degrees , beta = 90.00 degrees , gamma = 120.00 degrees . The structure of p/SLA-2*04:02:02 was analyzed. The results revealed that Glu24, Met68, Gly76, and Gln173 in PBG of SLA-2*04:02:02 are different from other MHC I. Furthermore, Asn63 is different from other SLA I. Gln57, Met174 and Gln180 in PBG of SLA I are different from other species' MHC I. All of these features are different from known mammalian peptide-MHC class I complexes (referred to as p/MHC I). In addition, P4-His, P6-Val, and P8-Pro in the peptide were exposed, and these residues as epitopes can be presented by SLA-2*04:02:02. This study not only provides a structural basis for peptide presentation by SLA-2, but also screens one potential FMDV CTL epitope. The results may be of interest in future vaccine development.

Crystallization of SLA-2*04:02:02 complexed with a CTL epitope derived from FMDV.,Ning S, Wang ZB, Qi P, Xiao J, Wang XJ Res Vet Sci. 2020 Feb;128:90-98. doi: 10.1016/j.rvsc.2019.11.002. Epub 2019 Nov , 7. PMID:31760318[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Ning S, Wang ZB, Qi P, Xiao J, Wang XJ. Crystallization of SLA-2*04:02:02 complexed with a CTL epitope derived from FMDV. Res Vet Sci. 2020 Feb;128:90-98. PMID:31760318 doi:10.1016/j.rvsc.2019.11.002

6a6h, resolution 2.31Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA